198967-22-5Relevant articles and documents
Construction of complex bisether-bridged medium-sized cyclic compounds from o-(1-(acyloxy)propargyl)benzaldehydes under base and acid catalysis
Zhao, Yun-Long,Cheng, Ying
, p. 11114 - 11124 (2019)
We report herein our serendipitous discovery of the rapid and straightforward accesses to unprecedented diverse complex molecular structures from readily available starting materials. Catalyzed by 1,8-diazabicyclo[5.4.0]undec-7-ene under mild conditions, o-(1-(acyloxy)propargyl)benzaldehydes 1 underwent efficient and selective dimerization reactions to produce novel complex bisether-bridged tricyclic products 3 and 4. The reactions proceeded most probably through dimerizations between 3-methylene-3H-isochromene intermediate and its zwitterionic resonance structures which were generated from a concerted 6-πelectrocyclic ring closure reaction from the initially formed (2-formylphenyl)allene intermediates derived directly from o-(1-(acyloxy)propargyl)benzaldehydes. Treatment of the resulting product simply with NaOEt in ethanol and aqueous HCl, respectively, enabled further development of complex molecular diversities.
BORON CONTAINING COMPOUNDS AND THEIR USES
-
Paragraph 0205-0206, (2021/01/23)
The present disclosure contemplates a boron-containing compound, a composition containing a pesticidal effective amount of that compound dissolved or dispersed in a carrier medium, and a method of reducing, ameliorating, or controlling an infestation by a pest, particularly a fungus, by administering a contemplated composition to a plant or animal in need.
SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION
-
, (2008/06/13)
The present invention relates to certain novel benzylamine derivatives of formula (I) wherein R and R, which may be the same or different, are each selected from C6-12aryl, C2-14heteroaryl, C6-12arylC1-6alkyl, C2-14heteroarylC1-6alkyl (where the alkyl, aryl or heteroaryl moiety may be optionally substituted by one or more substituents selected from C1-6alkoxy, C1-6alkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-12aryl, C2-14heteroaryl, halogen, amino, hydroxy, haloC1-6alkyl, nitro, C1-6alkylthio, sulphonamide, C1-6alkylsulphonyl, hydroxy-C1-6alkyl, C1-6alkoxycarbonyl, carboxyl, carboxyC1-6alkyl, carboxamide and C1-6alkylcarboxamide), hydrogen, C1-6alkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C2-6alkenyl, C2-6alkynyl and C1-6alkoxyC1-6alkyl (where the alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, or alkoxyalkyl moieties may be optionally substituted by one or more substituents selected from amino, halogen, hydroxy, C1-6alkylcarboxamide, carboxamide, carboxy, C1-6alkoxycarbonyl, C1-6alkylcarboxy and carboxyC1-6alkyl) or one of R and R are as hereinbefore defined and one is hydroxy; R and R, which may be the same or different, are each selected from C6-12aryl, C2-14heteroaryl, C6-12arylC1-6alkyl, C2-14heteroarylC1-6alkyl (where the alkyl, aryl or heteroaryl moiety may be optionally substituted by one or more substituents selected from C1-6alkoxy, C1-6alkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-12aryl, C2-14heteroaryl, halogen, amino, hydroxy, haloC1-6alkyl, nitro, C1-6alkylthio, sulphonamide, C1-6alkylsulphonyl, hydroxyC1-6alkyl, C1-6alkoxycarbonyl, carboxyl, carboxyC1-6alkyl, C1-6alkylcarboxamide and carboxamide), hydrogen, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-6alkyl, C4-6cycloalkenyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy-C1-6alkyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, cyano, carboxyl, C1-6alkylcarboxy and carboxyC1-6alkyl (where the alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, or alkoxyalkyl moieties may be optionally substituted by one or more substituents selected from amino, hydroxy, C1-6alkylcarboxamide, carboxamide, carboxy, C1-6alkoxycarbonyl, C1-6alkylcarboxy and carboxyC1-6alkyl); or one of R or R together with one of R or R and the N atom to which it is attached form a 5- or 6-membered heterocyclic ring. R represents one or more ring substituents selected from halogen, hydrogen C1-6alkyl and C1-6alkoxy; and R represents a single ring substituent of formula (A) wherein the dotted line represents an optional bond; Y is oxygen or -NR (where R is hydrogen or C1-6alkyl) and R represents one or more substituents selected from hydrogen, halogen, haloC1-6alkyl, C1-6alkyl and C1-6alkoxy; or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.
